Vyzulta®
(Latanoprostene Bunod)
Vyzulta is an eye drop medicine used to lower high eye pressure in people with open-angle glaucoma or ocular hypertension. Reducing high eye pressure helps prevent damage to the optic nerve, which can lead to vision loss.
How to Use Vyzulta
Use one drop of Vyzulta in the affected eye(s) once every evening.
If you are using more than one type of eye drop, make sure to wait at least five minutes between applying each medicine.
Do not use Vyzulta more than once a day—it may make the medicine less effective.
Common Side Effects
Like most medications, Vyzulta can cause some side effects. The most common ones include:
Redness in the eyes
Mild eye irritation
Eye pain
A slight stinging when you apply the drops
These side effects are usually mild and go away on their own. If you have any concerns or more serious side effects like vision changes or ongoing eye discomfort, contact your doctor.
Important Information
Changes in Eye Color: Vyzulta may cause your iris (the colored part of your eye) to darken over time. This change could be permanent.
Eyelash Changes: You might notice your eyelashes becoming longer, thicker, or darker while using Vyzulta. These changes usually go away after you stop using the medication.
Macular Edema: If you have a higher risk for swelling in the back of the eye (macular edema), tell your doctor before using Vyzulta.
Using Contact Lenses: Take out your contact lenses before using Vyzulta. You can put them back in 15 minutes after applying the drops.
How Vyzulta Works
Vyzulta helps lower eye pressure by helping the fluid in your eye drain better. It works through two pathways: the trabecular meshwork (the main drainage system of the eye) and the uveoscleral pathway (another way fluid leaves the eye). By improving drainage, Vyzulta helps reduce pressure inside the eye, protecting your vision.
For more information, talk to your eye doctor or visit the Vyzulta website.
How Vyzulta Works (In-Depth)
Vyzulta (latanoprostene bunod) is a prostaglandin analog designed to lower intraocular pressure (IOP) by increasing fluid drainage through both the trabecular meshwork and uveoscleral pathway.
Latanoprostene is converted into latanoprost acid, which increases fluid outflow through the uveoscleral pathway by relaxing the muscles around this drainage route. This helps to enhance fluid drainage and lower eye pressure.
Bunod, the other component of Vyzulta, is converted into nitric oxide. Nitric oxide relaxes the smooth muscle cells within the trabecular meshwork, allowing more aqueous humor to exit through the primary drainage route. This nitric oxide release improves the flow through the trabecular meshwork, helping to further reduce eye pressure.
By targeting both the trabecular meshwork and the uveoscleral pathway, Vyzulta provides a comprehensive approach to reducing intraocular pressure, helping to protect the optic nerve from damage associated with glaucoma.
If you're exploring other options, Rocklatan and Simbrinza are also commonly prescribed for managing intraocular pressure and glaucoma.
